Senior Leadership

Dror Ben-Asher, Co-Founder of RedHill, was previously with ProSeed Capital, a European corporate finance boutique. Mr. Ben-Asher is a graduate of the University of Oxford (M.Jur.) and completed LL.M. studies at Harvard University. At Harvard, Mr. Ben-Asher was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror Ben-Asher received an LL.B. with distinction (First Class Honours) from the University of Leicester.

Adi Frish brings extensive business development and transactional experience to RedHill. Prior to joining RedHill, he served as VP Business Development at Medigus (TASE: MDGS). Mr. Frish was previously a partner at Y. Ben-Dror & Co. He is a graduate of Bar Ilan University (LL.M.) and Essex University (LL.B. with Honors).

June Almenoff, M.D., Ph.D., FACP is an accomplished executive with over twenty years’ experience in the pharmaceutical industry. Dr. Almenoff served as Principal Executive Officer and Chief Medical Officer of Furiex Pharmaceuticals, leading the development of Viberzi® up to its approval in 2015. Prior to joining Furiex, Dr. Almenoff worked at GlaxoSmithKline (GSK), where she held various positions of increasing responsibility. During her twelve years at GSK, Dr. Almenoff served as Vice President in the Clinical Safety organization and led the development of pioneering systems for minimizing risk in drug development. Dr. Almenoff was appointed as a member of RedHill’s Scientific Advisory Board in 2016. She has recently served as a Board member and advisor to numerous biopharma companies. She received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Mt. Sinai School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine.

Gilead Raday previously served as interim CEO of Sepal Pharma, and as a director at TK Signal and Morria Biopharmaceuticals. He is a graduate of the University of Cambridge (M.Sc. in Bioscience Enterprise) and the Hebrew University of Jerusalem (M.Sc. Neurobiology, BSc Mathematics and Biology).

With more than 25 years of experience in the pharmaceutical industry, Mr. Scruggs brings extensive knowledge in commercial operations and business development. He most recently served as executive vice president of business development at Salix Pharmaceuticals, Inc. (“Salix”), until its acquisition by Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.). Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals, Inc. and Watson Pharmaceuticals, Inc. At Salix, Mr. Scruggs helped build the company’s commercial organization, serving in various sales and commercial trade-related positions. He was appointed executive vice president in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix’s innovative products and intellectual property. Mr. Scruggs also served as chairperson of the board of directors of Oceana Therapeutics, Salix’s European subsidiary.

Prior to joining RedHill, Guy Goldberg served as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. Previously, Mr. Goldberg was a member of the investment team at ProQuest Investments, a healthcare focused venture capital firm. He previously served as a consultant at McKinsey & Company and holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.

Prior to joining RedHill, Dr. Fathi served as Director of Research Operations at XTL Biopharmaceuticals. He was previously at VivoQuest, PharmaGenics, Metrigen, Enzo Biochem and the Harvard Institute of Chemistry and Cell Biology. Dr. Fathi graduated from Rutgers University (Ph.D. and Post-Doctoral Fellow) and Texas Tech University (BSc).

Patricia Anderson has over 30 years of experience in regulatory affairs, developing numerous successful submissions to regulatory agencies across North America and Europe. Prior to joining RedHill, Ms. Anderson served as VP of Regulatory Services at MAPI SRS and as a member of the Executive Steering Committee for SRS, responsible for the business unit for regulatory consulting. She also served in various regulatory affairs positions at PharmApprove International Regulatory Consultants, Hyal Pharmaceutical Corporation and Bayer Canada. Ms. Anderson graduated with a B.Sc. in Biology from York University and a M.Sc. in Regulatory Affairs from University of Hertfordshire. Ms. Anderson received a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society and Ms. Anderson was also honored as a Fellow of the Regulatory Affairs Professional Society.

Patrick McLean, our dear friend and colleague, passed away in February 2021. He will be greatly missed.